Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma

Organ transplant recipients (OTRs) on cyclosporine A (CSA) are prone to catastrophic cutaneous squamous cell carcinoma (SCC). Allograft-sparing, cancer-targeting systemic treatments are unavailable. We have shown increased risk for catastrophic SCC in OTRs via CSA-mediated induction of IL-22. Herein...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Abikhair Burgo, Melody, Roudiani, Nazanin, Chen, Jie, Santana, Alexis L., Doudican, Nicole, Proby, Charlotte, Felsen, Diane, Carucci, John A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171807/
https://ncbi.nlm.nih.gov/pubmed/30185657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.120750
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg